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Summary
 
The striking and unique structural feature of the T cell receptor (TCR) 
 
b
 
 chain is the bulky sol-
vent-exposed FG loop on the C
 
b
 
 domain, the size of almost half an immunoglobulin domain.
The location and size of this loop suggested immediately that it could be a crucial structural link
between the invariant CD3 subunits and antigen-recognizing 
 
a
 
/
 
b
 
 chains during TCR signaling.
However, functional analysis does not support the above notion, since transgene coding for TCR
 
b
 
 chain lacking the complete FG loop supports normal 
 
a
 
/
 
b
 
 T cell development and function.
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T
 
he
 
 a
 
/
 
b
 
 T lymphocytes use clonally distributed TCR
to recognize cell-bound antigens, usually in the form
of peptides embedded in MHC molecules. The 
 
a
 
/
 
b
 
 TCR
is an oligomeric complex containing variable, covalently
bound 
 
a
 
 and 
 
b
 
 chains responsible for antigen recognition
and four noncovalently associated monomorphic subunits,
CD3
 
d
 
, 
 
g
 
, 
 
e
 
, and 
 
z
 
 chain. The invariant subunits are crucial
for efficient assembly of the TCR and, hence, for surface
expression (1). In addition, they couple extracellular ligand
binding into cytoplasmic signaling machinery and, there-
fore, form an essential and the most proximal component
of TCR signal transduction (2).
Although some of the sequential biogenesis steps of the
TCR complex are quite well-characterized, the final com-
plex on the cell surface is surprisingly poorly defined: not
only is the overall topology of the complex unknown, but so
is even the basic stoichiometry of the TCR, the most com-
monly proposed structure being TCR
 
abz
 
2
 
CD3
 
dge
 
2
 
 (1).
Recently resolved three-dimensional structures of ecto-
domains of TCR 
 
b
 
 and 
 
a
 
/
 
b
 
 chains have now offered some
potential insights into the puzzle of the TCR complex to-
pology (3–6). The most striking feature of the structure of
the C
 
b
 
 domain is the large 14–amino acid long FG loop
that protrudes freely into the solvent on the external face of
the C
 
b
 
 domain. It was soon proposed that this loop would
interact with CD3 and, therefore, be part of the relay team
in TCR signal transduction (3). Recent more detailed struc-
tural analyses and simple elegant antibody/epitope mapping
of the TCR have added further details and suggested that
the loop would form part of the interface between CD3
 
e
 
and the C
 
b
 
 domain (6, 7).
Here we report our finding that the TCR 
 
b
 
 chain lacking
the complete 14–amino acid FG loop is able to support nor-
mal T cell development and function in transgenic mice.
 
Materials and Methods
 
TCR-
 
b
 
 Mutagenesis.
 
A retroviral expression vector LXSN
coding for the wild-type TCR 
 
b
 
 chain (V
 
b
 
8.2-J
 
b
 
2.1) cDNA was
used as template for mutagenesis. Deletion of the region corre-
sponding to the 14–amino acid FG loop of the C
 
b
 
 domain was
performed by linking PCR. A 1:1 ratio of the products from PCR 1
(5
 
9 
 
oligo of V
 
b
 
8.2 GAATTCCTTGAGCTCAAGATGGGCTC-
CAGGCTCTTC [oligo A] and 3
 
9 
 
oligo spanning the deletion
 
GTTCTGTGTGACCCCATGGAACTGCACTTGGCAGCG)
and PCR 2 (5
 
9 
 
oligo spanning the deletion CAGTTCCATGGG-
GTCACACAGAACATCAGTGCAGAG and 3
 
9 
 
oligo containing
the stop codon AGGATCCTCATGAGTTTTTTCTTTTGAC
[oligo B]) was used as template for PCR 3 (oligo A and B). The
PCR product was digested with EcoRI and BamHI and cloned
into an EcoRI and BamHI–opened retroviral vector LXSN. Dele-
tion (underlined amino acids 231–244) GLSEEDKWPEGSPKPV
was then verified by DNA sequencing. Transgenic vectors were as
described previously (8).
 
Transfection of Cell Lines.
 
Infectious retroviral stocks were
generated by transfecting packaging cell lines GP
 
1
 
E-86 (9) with
retroviral expression vectors LXSN (neomycin resistant) coding
for wild-type or mutant TCR 
 
b
 
 chain, or vectors LXSP (puro-
mycin resistant) coding for wild-type TCR 
 
a
 
 chain (V
 
a
 
4-J
 
a
 
47).
The supernatants from appropriately selected packaging cell lines
were used to infect TCR
 
2
 
 hybridomas. The wild-type 
 
b
 
 or mu-
tant 
 
b
 
 chain were first introduced into the hybridomas, and after
neomycin selection (G418, 1 mg/ml) these lines were superin-
fected separately with TCR 
 
a
 
 chain as described previously (10). 
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The cell lines were then cultured in IMDM supplemented with
2% FCS, G418, and puromycin (10 
 
m
 
g/ml). TCR expression
was tested by FACS
 
®
 
 as soon as 4 d after selection. Stable trans-
fectants were maintained in G418 and puromycin–containing
medium.
 
Mice.
 
BALB/c and C56BL/6 mice were purchased from
IFFA-Credo. The TCR-
 
b
 
 knock-out mice have already been
described (11), and were bred in our specific pathogen–free ani-
mal facility with the wild-type TCR-
 
b
 
 or mutant TCR-
 
b
 
 trans-
genic mice.
 
Flow Cytometry and Antibodies.
 
Immunofluorescence stainings
were done as described previously (12). Flow cytometric analysis
was performed with a FACSCalibur™ equipped with CellQuest
software (Becton Dickinson). The reagents used were mAbs bio-
tinylated 145-2C11 (anti-CD3
 
e
 
), PE-labeled RM4-5 (anti-CD4)
and FITC-labeled H57-597 (anti-C
 
b
 
) (13), B20.1 (anti-V
 
a
 
2),
RR3-16 (anti-V
 
a
 
3.2), B21-14 (anti-V
 
a
 
8), and RR8-1 (anti-
V
 
a
 
11.1, 2) (all seven mAbs purchased from PharMingen), Cy5-
labeled 53-6.7 (anti-CD8), fluorescein-succinimidyl-ester (FLUOS)-
labeled F23.1 (anti-V
 
b
 
8.1, 2, 3) (14), and second-step reagent
streptavidin-allophycocyanin (APC) (Molecular Probes, Inc.).
 
T Cell Functional Assays.
 
For T cell proliferation, 2 
 
3
 
 10
 
5
 
spleen cells were cultured in triplicate with various concentrations
of staphylococcal enterotoxin B (SEB) and SEC 2 superantigens
in 200 
 
m
 
l of IMDM supplemented with 10% FCS in 96-well flat-
bottomed plates. Proliferative responses were assessed after 48 h
of culture. Cultures were pulsed 8 h before harvesting with 1 
 
m
 
Ci
[
 
3
 
H]TdR (40 Ci/nmol; Radiochemical Center, Amersham Phar-
macia Biotech), and incorporation of [
 
3
 
H]TdR was measured by
liquid scintillation spectrometry. Helper T cell responses were
tested by immunizing mice (three per group) with 100 
 
m
 
g of NIP-
OVA in CFA in the tail base. For control, mice received PBS in
CFA (referred to as CFA only in Fig. 3). After 14 d, sera from im-
munized mice were pooled and tested for the presence of anti-NIP
IgG by ELISA as described (15). Plates coated with 5 
 
m
 
g/ml of
NIP-BSA and then blocked with PBS/1% BSA received dilutions
of the sera. Binding of the anti-NIP IgGs was revealed by alkaline
phosphatase–conjugated goat anti–mouse IgG (Southern Biotech-
nology Associates). Allogeneic killer cells were generated as de-
 
scribed previously (8). In brief, 10
 
7
 
 responders (H-2
 
b 
 
splenocytes
from wild-type TCR-
 
b
 
 or mutant TCR-
 
b
 
 transgenic mice) were
cultured with 10
 
7
 
 x-irradiated stimulators (H-2
 
d
 
 splenocytes from
BALB/c mice). After 5 d, various numbers of responder cells
(numbers used to calculate the E/T ratios) were cultured with 10
 
4
 
Na
 
2
51
 
CrO
 
4
 
-labeled target LPS blasts. After 4 h, supernatant was
harvested. Some wells contained only labeled targets with or with-
out 0.01 M HCl/10% SDS containing medium to determine max-
imum and spontaneous release, respectively. Data are presented as
percentage of killing 
 
5 
 
[(experimental release 
 
2
 
 spontaneous re-
lease)/(total release 
 
2
 
 spontaneous release)] 
 
3
 
 100.
 
Results and Discussion
 
Surface Expression of TCR Containing the Mutant, FG Loop–
deleted 
 
b
 
 Chain.
 
To test whether the deletion of the com-
plete 14–amino acid FG loop in the C
 
b
 
 domain would be
deleterious for the TCR assembly and surface expression,
we transfected TCR
 
2
 
 T cell thymoma 58 with retroviral
vectors coding for either a control or a mutant 
 
b
 
 chain to-
gether with a wild-type 
 
a
 
 chain (10). To our initial sur-
prise, the TCR surface expression was only slightly lower
in the mutant case (Fig. 1 A). However, we must point out
that the observed 30–50% reduction in the surface expres-
sion represents a handicap in the TCR assembly which, al-
though small, is real since we have used a very efficient ret-
roviral transfection system that allows us to create bulk
transformants containing thousands of individual clones and
which, therefore, provides us with a reliable statistical aver-
age. Functional analyses of these transfectomas consistently
showed that the cells transfected with the mutant TCR 
 
b
 
chain responded slightly less (about threefold) to antigenic
stimulation as exemplified here by the dose–response curves
to influenza hemagglutinin peptide HA 110-119 (Fig. 1 B)
or SEC 3 superantigen (Fig. 1 C).
 
Derivation of TCR 
 
b
 
 Chain Transgenic Mice.
 
To more rig-
Figure 1. The mutant TCR b chain is functionally expressed on the cell surface. (A) Cells transfected with TCR a chain together with a control b
(ab) or mutant b chain (ab-loop2) were stained with biotinylated anti-CD3e mAb followed by streptavidin-APC. Staining of cells transfected with mu-
tant b chain only is shown as negative control. Numbers represent the mean of fluorescence intensity of CD3 staining. (B and C) Functional response of
105 TCR transfectants (ab, d; ab-loop2, s) cultured with 105 irradiated antigen-presenting cells (B cell lymphomas A20) and the indicated concentra-
tions of influenza hemagglutinin peptide HA 110-119 (B) or superantigen SEC 3 (C). After 20 h, the culture supernatant was collected and tested for the
presence of lymphokines using the IL-2–dependent proliferation assay of HT2 cell lines.1681 Degermann et al. Brief Definitive Report
orously assess the functional potential of the TCR contain-
ing the mutant b chain in normal physiological settings in
vivo, we generated transgenic mice expressing either a
wild-type or a loop-deleted version of the TCR b chain.
The b transgenes, as in the above transfection studies, were
derived from 14.3d T cell hybridoma expressing the TCR
specific for influenza hemagglutinin peptide HA 110-119
in the context of I-Ed MHC class II molecules (16). In fact,
it was the very same b chain (Vb8.2-Jb2.1) whose three-
dimensional structure was first solved, thus providing us
with the inspiration for the current study (3). Two charac-
teristics of the transgenic lines used here were considered
essential for straightforward interpretation of the data. First,
the level of a/b TCR expression was identical in both
lines (Fig. 2). Presumably the small handicap of the mutant
b chain in the TCR assembly could be compensated by
higher intracellular expression. Second, both transgenes
were bred to TCR-b2/2 background to avoid any contri-
bution of endogenous b chains for the observed a/b T cell
behavior (11).
Mutant TCR b Chain Supports Normal a/b T Cell Devel-
opment. a/b T cell development proceeds undisturbed
and similarly in both TCR b chain transgenic lines as
shown by flow cytometric analysis of thymic and lymph
node cells (Fig. 2). Even the skewing into single positive
CD4 thymocytes, as noted earlier for our wild-type TCR-b
transgenic mice (8), occurs to the same extent in both lines.
As predicted, mAb H57-597 (anti-Cb [13]) does not bind
to mutant TCR b chain (Fig. 2 H [6]). Interestingly, mAb
F23.1 (anti-Vb8.1, 2, 3 [14]) binds equally well to both b
chains, whereas mAb MR5-2 (anti-Vb8.1, 2 [17]) fails to
react with the mutant, suggesting that the FG loop may
form part of the MR5-2 epitope (not shown). Since the
cellularity of thymi is normal in both cases, we assume that
pre-TCR–mediated T cell expansion occurs normally in
these mice.
Normal a/b T Cell Responses in Mutant b Chain Transgenic
Mice. Peripheral T cell responses were measured in sev-
eral types of assays, and none of them, to our disappoint-
ment, showed any significant differences between mice of
the different transgenic lines. The in vitro responses to anti-
TCR antibodies (not shown) and to SEC 2 and SEB super-
antigens were repeatedly similar in all mice tested (Fig. 3,
A and B). In addition, the in vivo CD41 T cell responses
measured by T cell help for hapten-specific IgG production
were basically indistinguishable between control and mu-
tant mice (Fig. 3 C). Finally, a/b T cells from mutant TCR
b chain transgenic mice made as vigorous cytotoxic T cell
responses against allogeneic targets as their control counter-
parts (Fig. 3 D). We also monitored the representation of
four different Va families by flow cytometry in peripheral
T cells in order to reveal any subtle in vivo biases, but none
were found (Table I). In addition, limited DNA sequence
analyses of Va 2 and 8 families from single a/b T cells
revealed no obvious “mutant”-specific features (data not
shown).
Concluding Remarks. Thus far, we have found only a
quantitative role in the TCR assembly process for the large
solvent-exposed FG loop on the Cb domain. In transfec-
tants, the TCR will assemble in the absence of the loop in
the b chain but slightly less efficiently compared with the
wild-type structure. Of course, the reduced surface expres-
sion leads to somewhat impaired function. However, we
were able to show in vivo that TCRs are functionally ex-
Figure 2. FACScan™ analysis of thymocytes or lymph node cells from
mutant TCR b chain transgenic mice. Thymocytes from littermate con-
trol (A and B), wild-type TCR-b (C and D), or mutant TCR-b (E and
F) transgenic mice were triple-stained with anti-CD8–Cy5, anti-CD4–
PE, and anti-Vb8 (F23.1-FLUOS) antibodies. Numbers in all dot plots
are percentages of total cells. Histograms represent Vb8 expression of
gated single positive CD41 thymocytes, and numbers show the mean of
fluorescence intensity of Vb8 staining. Lymph node cells from wild-type
TCR-b (G) or mutant TCR-b (H) transgenic mice were stained with
anti-Cb–FITC and anti-CD4–PE.1682 Mice Transgenic for a TCR b Chain Lacking the Cb FG Loop
pressed at the same level with or without the FG loop, and
we did not find any qualitative or quantitative differences
in their activity. This finding seems to rule out the models
where the FG loop has an absolute role in TCR signaling.
However, the apparent absence of any effect in vivo could
also be due to the fact that some subtle compensatory
mechanisms have been turned on in vivo (but not in cell
lines), e.g., TCR affinities could be modulated, or new car-
bohydrate structures on the Cb domain could partially re-
place the FG loop functionally. Interestingly, all nonmam-
malian species studied to date, including birds, amphibians,
reptiles, and fish, do not have the FG loop on their Cb do-
main (18); hence, our in vivo findings may not be that sur-
prising.
Figure 3. Functional analysis of periph-
eral T cells from syngeneic control mice
(WT), wild-type TCR-b ( b), or mutant
TCR-b (b-loop2) transgenic mice. Prolif-
erative response to SEB (A) or SEC 2 (B)
superantigens after 48 h of culture. Helper
T cell responses (C) assessed 14 d after im-
munization with NIP-OVA/CFA. Sera
from the immunized mice were tested for
the presence of anti-NIP IgGs by ELISA on
plates coated with NIP-BSA. (D) Alloge-
neic killer assay. Splenocytes from H-2b
control or transgenic mice were stimulated
for 5 d with allogeneic H-2d BALB/c cells.
Cytotoxic function was then tested on syn-
geneic H-2b (open symbols) or allogeneic
H-2d (filled symbols) Na2
51CrO4-labeled
target LPS blasts.
Table I. TCR Va Usage in Mutant TCR-b Transgenic Mice
Percent of CD41 Percent of CD81
Va21 Va3.21 Va81 Va111 Va21 Va3.21 Va81 Va111
b 22.7 6 1.0 0.7 6 0.2 3.0 6 0.1 1.5 6 0.4 7.7 6 1.8 1.0 6 0.1 4.5 6 0.1 1.2 6 0.2
b-loop2 22.7 6 0.9 0.5 6 0.1 2.6 6 0.3 2.3 6 0.3 7.6 6 1.1 1.4 6 0.6 3.6 6 0.7 2.0 6 0.3
Lymph node cells from TCR-b (b) or mutant TCR-b (b-loop2) transgenic mice were triple stained with the FITC-labeled anti-Va Abs, anti-CD4–
PE, and anti-CD8–Cy5. Results (three mice per group) are expressed as the percentage of stained cells 6 SD.1683 Degermann et al. Brief Definitive Report
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